Insulet Corporation (NASDAQ:PODD) showcases a high Return on Invested Capital (ROIC) of 16.28% and a Weighted Average Cost of ...

Abbott, Dexcom, Insulet, Medtronic and others are developing next-gen sensors, pumps and algorithms for type 2 diabetes ...

Shares of DexCom Inc. slipped 3.69% to $69.47 Thursday, on what proved to be an all-around poor trading session for the stock ...

A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its ...

The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

SAN DIEGO – DexCom has named Jon Coleman as chief commercial officer to oversee the company’s global commercial organization, including sales, marketing and customer experience.

Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...

CGMs are transforming health tracking for non-diabetics, providing insights into glucose levels and influencing dietary choices and athletic performance.

The U.S. FDA’s March 4, 2025, warning letter to Dexcom Inc. is a well-detailed but heavily redacted document explaining the agency’s misgivings about procedures such as monitoring of acetaminophen ...

Dexcom (Nasdaq:DXCM) has a new chief commercial officer with significant experience at another major medtech company.

DexCom Inc. closed 48.20% below its 52-week high of $142.00, which the company reached on March 26th.

DexCom (DXCM) announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for ...